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Objective: To evaluate the inﬂuence of hepatitis C virus on immunological and virological
responses  after highly active antiretroviral therapy initiation in human immunodeﬁciency
virus/hepatitis C virus coinfected patients compared to monoinfected human immunode-
ﬁciency  virus-infected patients.
Methods:  The study enrolled 65 human immunodeﬁciency virus-1-infected subjects who
initiated  highly active antiretroviral therapy and attended follow-up visits over 48 weeks
from  2008 to 2010. They were grouped based on hepatitis C virus-RNA results. Virological
and  immunological responses were monitored at baseline and at the end of weeks 12, 24,
36,  and 48.
Results: There were 35 human immunodeﬁciency virus monoinfected and 30 human
immunodeﬁciency virus/hepatitis C virus coinfected patients. In the present study human
immunodeﬁciency  virus/hepatitis C virus coinfection did not seem to inﬂuence CD4 T-
lymphocytes recovery. There was no difference between the curves of CD4 T-lymphocytesraise  of coinfected and monoinfected groups.
Conclusion: This prospective study conﬁrms that hepatitis C virus infection does not seem
to  be associated with impaired CD4 T-lymphocytes recovery after HAART.
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© 20oinfection of hepatitis C virus (HCV) in patients with human
mmunodeﬁciency virus (HIV) has become a frequent situa-
ion,  achieving a prevalence of nearly 30%, owing to common
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as  90% and 100%, respectively.3,4
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Clinical implications of HIV and HCV coinfection have been
the  focus of extensive research and controversial data. Sev-
eral  studies suggest a more  rapid immune deterioration (lower
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levels of CD4 T-lymphocytes); higher risk for progression to
acquired immunodeﬁciency syndrome (AIDS); increased HCV
load;  and a more  severe liver disease.5–7
The introduction of highly active antiretroviral therapy
(HAART) for the treatment of HIV-infected individuals has
shown  to decrease morbidity and mortality, as a result of sup-
pression  of HIV viremia, recovery of CD4 T-lymphocytes, and
restoring  immune function. Nonetheless, regarding the HCV
coinfection,  combined therapy yielded conﬂicting results.6
Some observational studies have found that HIV/HCV coin-
fected  patients have an impaired CD4 T-lymphocytes recovery
compared  with HIV monoinfected patients after initiating
HAART,5,8 whereas others have not found such an effect.6,9,10
Most studies have compared HIV/HCV populations with CD4 T-
lymphocytes count over 200 cells/mm3. After extensive search
at  Medline, the authors found no report in the literature about
immune  restoration in coinfected immunosupressed patients,
with  CD4 T-lymphocytes count near 100 cells/mm3.
In  this prospective study we aimed to assess the CD4 T-
lymphocytes count recovery after HAART in HIV and HCV
coinfected  patients comparing to HIV monoinfected patients.
Individuals  and  methods
Study  population
This was  a prospective study conducted at a tertiary hospital
in  Porto Alegre, Rio Grande do Sul, in Brazil, which included
patients from August 2008 through August 2010 initiating
HAART and who  achieved virological response in months 3
(reduction of 2-logs or higher in HIV viral load [VL]) and 6
(undetectable HIV VL). This criterion was  chosen to avoid poor
adherence  to HAART. All patients included were  previously
identiﬁed as HIV infected and hepatitis B virus negative. The
sample  was  categorized in two groups – HIV monoinfected
patients and HIV/HCV coinfected patients for whom demo-
graphic  characteristics, clinical and laboratory values, and
medical  history were  recorded at enrollment (before HAART
initiation)  and at medical consultation every 3 months there-
after.  Hepatic ﬁbrosis was  evaluated with liver biopsy, using
METAVIR  score.11
Laboratory  testing
Blood samples were  collected at enrollment and every 3
months,  including liver panel (alanine aminotransferases
[ALT], aspartate aminotransferases [AST], albumin), HIV VL
and  CD4 T-lymphocytes. Serologic testing for HCV infection
was  performed through ELISA (Abbott Axsym System, N.
Table 1 – Baseline characteristics of the study population prior 
Coinfected group (n = 30) 
Male, n (%) 22 (73%) 
Age (years) 41.8 ± 7.9 
Body Mass Index (BMI) 23.6 ± 2.1 
CD4+, median (cells/mm3) 116.3 ± 87.7 
HIV RNA (copies/mL) 182,000  1 3;1  7(5):551–554
Chicago,  IL, EUA) and polymerase chain reaction (PCR) for HCV-
RNA,  through AMPLICOR qualitative test (Roche Diagnostics,
Nutley, NJ, USA; detection limit: 50 UI/mL).
Statistical  analysis
All statistical analyses were performed using the SPSS® 10.0
statistical  package. The qualitative variables were  described
in  absolute frequency and percentage. The quantitative vari-
ables  were described in means and standard deviation. For the
analysis,  we used the chi-squared test, Spearman correlations,
and  the t-test for comparison of the variables in the study.
For  the evaluation of analysis of variance we  used Generalized
Estimating Equations.
Ethics
All individuals included agreed to join the study protocol.
Hospital Nossa Senhora da Conceic¸ão  Ethical Committee
approved the present study in 04/08/2008, number 136/08.
Results
Baseline  characteristics
From a total of 97 HIV-infected patients initially recruited, 65
(67%)  started HAART as their ﬁrst antiretroviral regimen and
were  included in the study. Of the patients who  returned for
the  second consultation, there was  no dropout. Baseline char-
acteristics  of the groups are summarized in Table 1. Thirty
patients  (46%) were HCV positive – all of them were  positive
for  HCV-RNA, and 35 (54%) patients were  HCV-RNA negative.
At  the end of 48 weeks of follow-up, only three (10%) patients
did  not reach the end point in the coinfected HIV/HCV group
and  three patients in the monoinfected group (8.6%). One
patient  (1.5%) discontinued therapy due to severe gastroin-
testinal symptoms, and ﬁve patients (7.5%) discontinued for
unexplained  reasons. Those patients had their data included
in  the analysis until they had virological conﬁrmation of dis-
continuation of therapy.
Intravenous  drug use was the main route of HCV infection
in  the coinfected group, with a total of 20 patients (64.5%). The
percentage  of males was  very similar in both groups. Compar-
ing  coinfected with monoinfected patients, the HCV infected
group  had higher mean age, but the difference was  not statis-
tically  signiﬁcant (41.8 versus 38.8 years). None of the patients
included  were  using alcohol or drugs during the study.
Regarding HAART, in the coinfected group the regimen was
two  nucleoside-analog reverse-transcriptase inhibitor (NRTI)
to HAART introduction.
Monoinfected group (n = 35) p
23 (66%) >0.05
38.8 ± 10.1 0.09
24.3 ± 3.6 0.68
117 ± 101.6 0.97
207,000 0.56
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Table 2 – CD4 T-lymphocytes variation over 12 months of evaluation.
CD4+, median cells/mm3 Coinfected group (n = 30) Monoinfected group (n = 35) p
Baseline (before HAART) 116.3 ± 87.7 117 ± 101.6 0.97
Month 3 201.4 ± 176.9 230 ± 158.4 0.53
Month 6 228 ± 152.8 251 ± 140.2 0.58
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On the other hand, Sulkowski et al. in a prospective cohort
study  of 1955 coinfected patients found no difference in the
increase  in CD4 T-lymphocyte counts during HAART in HCV
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lus non-nucleoside-analog reverse-transcriptase inhibitor
NNRTI)  in 21 (70%) of the patients versus 30 (85%) in the
onoinfected group. Only 9 (30%) patients of the coinfected
roup  were  on two NRTI and a protease inhibitor (PI) versus 5
15%) monoinfected patients.
Regarding  coinfected group, patients were predominantly
f  HCV genotype 1 (n = 22, 73%). No patient had diagnosis of
irrhosis.  Hepatic biopsy, evaluated by METAVIR score,9 was
erformed  in 16 of the 30 coinfected patients, and 12% had
epatic  ﬁbrosis grade 1, 50% had grade 2 and 6% had grade 3.
hirty-two  percent had no ﬁbrosis (grade 0) on hepatic biopsy.
IV  viral  load  response
oinfected and monoinfected patients had similar HIV
L  before initiation of HAART (182,000 × 207,000 copies/mL,
 = 0.51). Because of the study design, as shown in the “Meth-
ds”  section, all patients had reduction of at least of 2 logs in
onth  3 and undetectable HIV VL in month 6. The magnitude
f  decline in HIV-1 VL in both groups after HAART initiation
as  similar.
mmunological  response
mmunological response in both groups was  assessed by CD4
-lymphocytes counts after HAART introduction and at every
hree  months until the end of 12-month period.
There were  no statistical differences in CD4 T-lymphocytes
ounts between the groups during the entire study, using
onferroni correction. Changes in the CD4 T-lymphocytes sub-
ets are summarized in Table 2 and Fig. 1. At the beginning
f  HAART 13 coinfected (44%) and 20 monoinfected patients
57%)  had CD4 T-lymphocytes below 100 cells/mm3.
After 48 weeks of treatment with HAART, there was  a signif-
cant  increase in the percentage and absolute number of CD4
-lymphocytes, in both groups, but no statistically signiﬁcant
ifferences were  found.
Using  Generalized Estimating Equations, the most appropriate
est  for evaluation of behavior of CD4 T-lymphocytes varia-
ion  during the 48 weeks, there was  no difference between the
roups  (p = 0.402). CD4 T-lymphocytes curves of coinfected and
onoinfected  patients after HAART introduction were similar,
s  shown in Fig. 1.
iscussionhe present study intended to examine the impact of HCV
nfection  on the extent of CD4 T-lymphocytes recovery after
AART  initiation in a cohort of HIV-1/HCV coinfected patients
ompared  to HIV-1 monoinfected patients.311 ± 143 0.21
293 ± 144.9 0.67
Our study differs from previous studies because we
evaluated actually immunosuppressed patients (CD4 T-
lymphocytes count around 100 cells/mm3) and we assessed
CD4  T-lymphocytes increase only in patients with virologi-
cal  response in three months (reduction of 2-logs or higher in
HIV VL) and six months (undetectable HIV VL). This approach
has  some clear advantages once it eliminates the inﬂuence of
potential  differences in HAART adherence and drug potency
between  HCV infected and HCV uninfected patients.
There are conﬂicting results as to whether HCV infection
does  or does not have a deleterious effect on the course of
HIV  infection. However, most authors support a delay in CD4
T-lymphocytes recovery in HIV/HCV coinfected when com-
pared  to HIV monoinfected patients.5,8,12,13 Antonucci et al.
support  a direct role of HCV viremia as a potential limitation of
CD4  T-lymphocytes response to HAART.8 Santín et al. suggest
that  HIV/HCV coinfection blunts early immune restoration
during treatment with HAART, with a delay in the CD4 T-
lymphocytes recovery in HIV/HCV coinfected patients.5 Potter
et  al. believes that CD4 cell progression is negatively affected
by  the presence of HCV replication. Additionally they suggest
that  active HCV infection affects immune restoration in coin-
fected  patients even after years of HAART exposure.13 Many
authors  support the concept that after HIV-1 viral replication
is  kept under control, those differences in CD4 T-lymphocytes
recovery disappeared, ranging from one to four years in dif-
ferent  studies.5,12,14Period
Fig. 1 – CD4 T-lymphocytes variation over 48 weeks of
evaluation.
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infected compared with HCV uninfected patients. Also, no
difference  was  detected in the risk of acquiring an AIDS-
deﬁning illness or the risk of death when comparing both
groups.15 Fuping et al. evaluated 175 HIV/HCV coinfected and
HIV  monoinfected patients suggesting that HCV/HIV coinfec-
tion  does not affect immunological and virological responses
to  HAART. However, HCV coinfected patients were  at higher
risk  for drug reactions, such as rash and hepatotoxicity, to all
HAART  regimens,16,17 especially those treated with Nevirapine
or  Ritonavir.7,18,19
In the present study, we  provide evidence that HIV/HCV
coinfection does not seem to inﬂuence CD4 T-lymphocyte
recovery in these patients compared with HIV monoinfected
patients. The evaluation of analysis of variance with General-
ized  Estimating Equations between groups showed no difference
between  CD4 T-lymphocytes increment of coinfected and
monoinfected groups.
Because  of the massive prevalence of genotype 1 in HCV-
infected  patients, it was  not possible to assess differences of
immunological  restoration according to HCV genotype. It is
possible that inclusion of more  patients or longer follow-up
could  reveal signiﬁcant differences between the groups, but
with  the present study, we can rule out large and clinically
relevant differences. Additionally absence of HCV viremia is
an important limitation of our study, since it would interfere
in  CD4 T-lymphocytes restoration.
Conclusion
To the best of our knowledge, this is the ﬁrst prospec-
tive study that evaluated immunosuppressed patients, with
CD4  T-lymphocytes count around 100 cells/mm3. Most stud-
ies  published have included patients with higher levels of CD4
T-lymphocytes at baseline.
Finally, data from this prospective study conﬁrm that HCV
infection  does not seem to be associated with impaired CD4
T-lymphocytes response to HAART.
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